Listed

Integra Lifesciences Holdings Corp

IARTNasdaqCIK 917520HealthcareFiscal year ends Dec 31

Latest reported revenue, Q3 FY2026$411.2mRevenue, Q3 FY2026, three months to 2026-09-30$411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 23, 2026.

Latest quarter: Q3 FY2026

Three months to Sep 30, 2026, against the same quarter a year earlier.

  • Revenue$411.2mRevenue, Q3 FY2026, three months to 2026-09-30$411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure+2.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin4.6%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure+1.7 pts on a year earlier
  • Net margin3.6%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $14.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure+5.0 pts on a year earlier
  • Diluted EPS$0.19Diluted EPS, Q3 FY2026, three months to 2026-09-30$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figureSign changed from a year earlier
  • Free cash flow$85.7mFree cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: $96.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-23, accession 0000917520-26-000077. Derived: 9-month figure less the 6-month figure.Capital expenditure: $10.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-23, accession 0000917520-26-000077. Derived: 9-month figure less the 6-month figure.Report this figure+232.9% on a year earlier

Last eight quarters

Full statements
Revenue$411.2mOperating margin 4.6%
Diluted EPS$0.19, Q3 FY2026
Free cash flow$85.7m, Q3 FY2026
Integra Lifesciences Holdings Corp, key figures for the last eight quarters
Line itemUnitQ4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30Shape over the periods
Revenue$m443Revenue, Q4 FY2024, three months to 2024-12-31$442.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure383Revenue, Q1 FY2025, three months to 2025-03-31$382.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure416Revenue, Q2 FY2025, three months to 2025-06-30$415.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure402Revenue, Q3 FY2025, three months to 2025-09-30$402.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure435Revenue, Q4 FY2025, three months to 2025-12-31$434.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure392Revenue, Q1 FY2026, three months to 2026-03-31$391.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure419Revenue, Q2 FY2026, three months to 2026-06-30$418.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure411Revenue, Q3 FY2026, three months to 2026-09-30$411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%8.0%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $35.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $442.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(4.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$15.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Revenue: $382.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure(123.4%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$512.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Revenue: $415.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure2.9%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $11.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $402.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure5.3%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $23.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $434.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure2.9%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $11.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Revenue: $391.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure4.6%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $19.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Revenue: $418.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure4.6%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure
Net margin%4.4%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $19.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $442.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(6.6%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$25.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $382.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure(116.5%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$484.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $415.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure(1.3%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $402.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure(0.4%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $434.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(1.2%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $391.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure1.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $418.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure3.6%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $14.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Revenue: $411.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(0.33)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure(6.31)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$6.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figurenot reported (Diluted EPS not reported)(0.06)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure0.06Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-29, accession 0000917520-26-000058.Report this figure0.19Diluted EPS, Q3 FY2026, three months to 2026-09-30$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-23, accession 0000917520-26-000077.Report this figure
Free cash flow$m21.1Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $50.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $29.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(40.2)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$11.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Capital expenditure: $28.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure(11.2)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-29, accession 0000917520-26-000058. Derived: 6-month figure less the 3-month figure.Capital expenditure: $20.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-29, accession 0000917520-26-000058. Derived: 6-month figure less the 3-month figure.Report this figure25.8Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $40.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-23, accession 0000917520-26-000077. Derived: 9-month figure less the 6-month figure.Capital expenditure: $15.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-23, accession 0000917520-26-000077. Derived: 9-month figure less the 6-month figure.Report this figure(5.4)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $17.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000917520-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(5.0)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $9.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Capital expenditure: $14.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0000917520-26-000041.Report this figure10.5Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $22.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-29, accession 0000917520-26-000058. Derived: 6-month figure less the 3-month figure.Capital expenditure: $12.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-29, accession 0000917520-26-000058. Derived: 6-month figure less the 3-month figure.Report this figure85.7Free cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: $96.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-23, accession 0000917520-26-000077. Derived: 9-month figure less the 6-month figure.Capital expenditure: $10.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-23, accession 0000917520-26-000077. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.64bnOperating margin −30.2%
Diluted EPS−$6.74, FY2025
Free cash flow−$31.1m, FY2025
Integra Lifesciences Holdings Corp, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1,542Revenue, FY2021, twelve months to 2021-12-31$1.54bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0000917520-24-000022.Report this figure1,558Revenue, FY2022, twelve months to 2022-12-31$1.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000917520-25-000017.Report this figure1,542Revenue, FY2023, twelve months to 2023-12-31$1.54bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure1,611Revenue, FY2024, twelve months to 2024-12-31$1.61bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure1,635Revenue, FY2025, twelve months to 2025-12-31$1.64bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%12.8%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $197.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-28, accession 0000917520-24-000022.Revenue: $1.54bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0000917520-24-000022.Report this figure15.3%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $238.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-25, accession 0000917520-25-000017.Revenue: $1.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000917520-25-000017.Report this figure7.2%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $111.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011.Revenue: $1.54bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure1.8%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $28.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011.Revenue: $1.61bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure(30.2%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$493.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011.Revenue: $1.64bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure
Net margin%11.0%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $169.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-28, accession 0000917520-24-000022.Revenue: $1.54bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0000917520-24-000022.Report this figure11.6%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $180.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-25, accession 0000917520-25-000017.Revenue: $1.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000917520-25-000017.Report this figure4.4%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $67.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011.Revenue: $1.54bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure(0.4%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011.Revenue: $1.61bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure(31.6%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$516.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000917520-26-000011.Revenue: $1.64bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure
Diluted EPS$ per share1.98Diluted EPS, FY2021, twelve months to 2021-12-31$1.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-28, accession 0000917520-24-000022.Report this figure2.16Diluted EPS, FY2022, twelve months to 2022-12-31$2.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-25, accession 0000917520-25-000017.Report this figure0.84Diluted EPS, FY2023, twelve months to 2023-12-31$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure(0.09)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure(6.74)Diluted EPS, FY2025, twelve months to 2025-12-31−$6.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure
Free cash flow$m264Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $312.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-28, accession 0000917520-24-000022.Capital expenditure: $48.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-28, accession 0000917520-24-000022.Report this figure222Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $264.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-25, accession 0000917520-25-000017.Capital expenditure: $42.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-25, accession 0000917520-25-000017.Report this figure73.1Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $140.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000917520-26-000011.Capital expenditure: $66.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure25.0Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $129.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000917520-26-000011.Capital expenditure: $104.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure(31.1)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $50.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000917520-26-000011.Capital expenditure: $81.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000917520-26-000011.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Integra Lifesciences Holdings Corp
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$191.9m10,684,103Added+364,934
Rubric Capital Management LP2026-06-30$139.3m7,753,934Unchanged
Invesco Ltd.2026-06-30$67.3m3,749,367Added+263,764
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$67.2m3,743,093Added+56,456
MORGAN STANLEY2026-06-30$64.5m3,593,079Added+8,924
PARADIGM CAPITAL MANAGEMENT INC/NY2026-06-30$61.8m3,439,098Reduced−573,600
FULLER & THALER ASSET MANAGEMENT, INC.2026-06-30$61.7m3,436,006Reduced−93,398
STATE STREET CORP2026-06-30$52.9m2,946,862Added+60,306
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$52.9m2,946,173Added+55,349
NEUBERGER BERMAN GROUP LLC2026-06-30$42.6m2,364,777Added+249,522

Recent filings

All 1,445 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Integra Lifesciences Holdings Corp, recent filings
FiledFormWhat it isAccession number
2026-10-2316:01 ET10-QQuarterly reportPeriod 2026-09-300000917520-26-000077
2026-10-2110:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000917520-26-000073
2026-10-1920:20 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-425271
2026-10-0921:26 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-419228
2026-10-0212:20 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000917520-26-000067
2026-09-0810:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000917520-26-000061
2026-07-2920:03 ET10-QQuarterly reportPeriod 2026-06-300000917520-26-000058
2026-07-2910:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000917520-26-000055
2026-05-0820:15 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000917520-26-000044
2026-05-0520:03 ET10-QQuarterly reportPeriod 2026-03-310000917520-26-000041

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
917520
Tickers
IART
Exchange
Nasdaq
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
INTEGRA LIFESCIENCES CORP (to 1999-03-31)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. Listed shows no prices and gives no investment advice.